Hormonal
Central nervous system (CNS) action of leptin and insulin is essential for maintaining body weight and fuel metabolism, with hypothalamic neurons (specifically POMC and AGRP/NPY populations) serving as primary mediators of their anorexigenic effects.
Your brain's ability to process signals from fat (leptin) and blood sugar (insulin) is the primary switch for hunger and energy use. In obesity, this switch gets stuck, making weight loss difficult despite high hormone levels. Restoring sensitivity to these signals is key to regulating energy homeostasis.
It has been ascertained that insulin and leptin action in the CNS, and here especially on neurons, is essential for decreasing the food intake (anorexigenic) and eventually weight reducing effects of these two hormones
Why this rating
Based on a comprehensive review of multiple species (mice, rats, baboons, men) and extensive genetic ablation studies.
Source
CNS leptin and insulin action in the control of energy homeostasis
Bengt‐Frederik Belgardt et al. · Annals of the New York Academy of Sciences · 2010
DOI 10.1111/j.1749-6632.2010.05799.x
More from this paper
- CNS insulin signaling regulates systemic glucose homeostasis primarily through POMC neurons, whereas its effect on body weight involves additional, less-defined neuronal populations.Good
- Obesity-induced CNS insulin and leptin resistance is driven by impaired blood-brain barrier transport, chronic low-grade inflammation (TNF-alpha, IL-6), and upregulation of negative regulators like SOCS3 and PTP1B.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →